Results from a Study with Immunocidin® Equine for Sarcoid Tumors Being Published in the Journal of Equine Veterinary Science

28 April 2020

Napanee, Ontario, Canada – NovaVive Inc., an animal health immunobiology company, announces that data from a study with its immunotherapy for the treatment of sarcoid tumors – Immunocidin® Equine – is being published in the Journal of Equine Veterinary Science (JEVS). A journal pre-proof is now available online. The article, “Evaluation of locally injected Mycobacterium cell wall fraction in horses with sarcoids”, was authored by Stephanie S. Caston and Brett A. Sponseller from the Iowa State University (ISU) College of Veterinary Medicine, Kararzyna A. Dembek, North Carolina State College of Veterinary Medicine (formerly at ISU), and Jesse M. Hostetter, University of Georgia College of Veterinary Medicine (formerly at ISU). 

Immunocidin Equine has regulatory approval in the U.S. and Canada for the treatment of sarcoids, the most common type of equine skin tumor. There are four different forms of sarcoids, and these tumors are often found around the eyes, head/face, neck, chest, and shoulder, or at the site of old scars. It is estimated that sarcoids affect 1 in 100 horses in North America and they are believed to be caused by bovine papilloma virus (BPV) transmitted by flies.

A variety of treatments have been used in the past, including local topical and injectable therapies; response to treatment may differ depending on a number of factors including type, stage, location and size of the tumor, as well as prior treatment. Some tumors appear to be cured with complete surgical removal, but wide surgical removal is not always feasible given tumor location.

In the ISU study, 17 horses with diagnosed sarcoids were enrolled. Their tumors were injected with Immunocidin Equine at the initial visit and then at 2-week intervals thereafter for an average of four injections per case. Nine of the cases (52.9%) were completely resolved at the end of the study period or at the time of final follow-up (an average of 9 months post-final treatment). Three cases (17.6%) were reported as improved, but not resolved. Another three cases were discontinued from the study as the tumors were not resolving after four treatments. One case involved two masses, one of which was resolved with treatment, while the other had small regrowth. The final case was lost to follow-up. All cases had mild to moderate swelling of the injection site, and some cases had discharge after two or more injections. No serious systemic side effects or complications were encountered during the study.

Based on their findings, the authors concluded that Immunocidin Equine was effective in 52.9% of the cases enrolled (that had a known outcome) after 2-5 injections. The treatment was deemed safe and, although the side effect of swelling occurred in every case, swelling of the injection site was transient and resolved with no treatment or with NSAID administration.

About NovaVive Inc.

NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 regulator-approved products in the U.S. One formulation has been developed as an anticancer therapy in dogs and horses. Other formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of horses and cattle or effectively treating viral equine respiratory disease. The Company’s development plan is to identify additional livestock and companion animal diseases that may be effectively treated with its immunotherapeutic technology platform. For more information about the Company, please visit www.NovaVive.ca, or contact:

Graeme McRae
Graeme.McRae@NovaVive.ca
Phone: 613-391-3837                                 

or        

Jennifer Shea

Jennifer.Shea@NovaVive.ca
Phone: 613-391-2097

Sign up to stay up-to-date with NovaVive news.